PCL Co., Ltd. (CEO Kim So-yeon) announced that it will participate in CES 2024, which will be held in Las Vegas, USA from Tuesday, January 9 to January 12, 2020 (local time) next year.
PCL is a company specializing in in vitro diagnostics and was listed on KOSDAQ in 2017. Through CEO Kim So-yeon’s nationally designated laboratory project (supported by the Ministry of Science and Technology), we have developed a 3D immobilization technology for compounds and proteins, and based on this SG CapTM source technology, we are presenting new indicators for multiplex immunodiagnosis. The company explains that it has launched the world’s first high-risk virus multi-immune diagnostic product based on original technology. We have also launched the ‘HiSU system’, a high-speed automated inspection equipment, and the ‘PCLOKII system’, a small on-site diagnostic equipment.
During the coronavirus pandemic, we developed a self-diagnosing kit for coronavirus using saliva and exported it to 50 countries around the world. Recently, together with Gangnam Severance Hospital and NHN Cloud, which was spun off from Naver, we are challenging medical appliances using AI, leading the future of digital healthcare. Its technological prowess has been recognized through designation as a Seoul-type small giant company, an innovative medical device company designated by the Ministry of Health and Welfare, designation as an innovative prototype by the Public Procurement Service, possession of national core technologies by the Ministry of Trade, Industry and Energy, and acquisition of a family-friendly company.
At CES 2024, PCL plans to showcase its ‘Smart Healthcare Platform’. This was introduced as being able to bring about innovation in medical diagnosis by solving problems caused by delays in medical care in emergency conditions such as cerebrovascular disease through more accurate testing beyond the traditional hospital environment. Advantages of the platform include compact medical devices that can be used at home, AI-based outcome analysis processes for early risk detection and timely diagnosis and treatment.
Collaboration with NHN Cloud and Gangnam Severance Hospital is expected to contribute to comprehensive data management and prevention of five major environmental diseases (Green Healthcare Cloud Platform). Additionally, prediction and management services for chronic cardiovascular disease can utilize IVD devices and machine learning to provide accurate risk assessment without the need for traditional testing systems.
A PCL official said, “Through our participation in this CES, we first want to use it as a stepping stone for disseminating a platform that can unfold the company’s leading vision. Second, PCL wants to utilize the metaverse concept to provide a virtual experience of future medical care. Lastly, our participation in CES 2024 is consistent with PCL’s strategy to create new markets through active localization and market entry strategies, such as past technology transfer agreements and the establishment of a production facility in Morocco.” “We want to expand on this success by signing a technology transfer MOU with a local partner in the same country.”
In particular, PCL has adopted environmental, social and governance (ESG) principles to export the ‘PCL OKII’ POCT diagnostic device, which can simultaneously diagnose various diseases such as Corona, respiratory disease and HCV, globally, especially to Africa and Africa. He emphasized that the focus is on countries with limited medical infrastructure, such as Southeast Asia.
An official said, “Full-cycle digital clone healthcare has been successfully launched through cooperation with NHN Cloud and Gangnam Severance, and in January 2024, PCL plans to launch PCLOKII, a digital healthcare for medical devices, and patent registration has been completed. It’s already done. In addition, we plan to launch a cardiovascular chronic disease prediction and management service, and the patent application for this has been completed.”
Meanwhile, ‘CES’, the world’s largest IT exhibition hosted by the Consumer Technology Association (CTA), is an exhibition where you can see the flow of innovative technologies around the world at a glance and is held every January in Las Vegas, USA. AVING News, which has covered CES for 18 consecutive years, has reported CES news around the world every year since 2006, and has been selected through ‘BEST OF CES’ and ‘BEST OF MADE IN KOREA’, which select the best innovative products, companies and technologies. has been in progress. In addition, CES on-site issues are vividly conveyed through ‘AVING LIVE’.
The CES 2024 Seoul Unified Hall will be operated at the largest scale in terms of exhibition area, number of participating companies, and number of participating supporters since Seoul City’s first participation in CES in 2020. The Seoul Integration Center, in which 13 organizations collaborate and participate, is an important step in Seoul’s efforts to make Seoul a mecca for startups, and 17 of the companies participating in the Seoul Integration Center proved this by receiving innovation awards. The participating institutions in the Seoul Unification Center are ▲SBA ▲Seoul Bio Hub ▲Campus Town ▲AI Yangjae Hub ▲Gwanak-gu ▲Yonsei University ▲Korea University ▲Chung-Ang University ▲Sogang University ▲Kookmin University ▲Hanyang University ▲Konkuk University ▲Kyunghee University. Not only the Seoul Metropolitan Government, institutions, and companies, but also supporters through industry-academia cooperation are matched 1:1 with companies, and 85 supporters, the largest number, will participate.
* Special reporters: Joseph Choe, Kidai Kim, Dongkwan Kim, Mokkyung Lee, Sangun Choi, Seung Hyun Nam, Sunghwan Kim, Taeuck Lim, Min Choi
→ Go to the CES 2024 news special page